Citi raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $469 from $378 and keeps a Buy rating on the shares post the Q4 report. Madrigal exceeded sales expectations for Rezdiffra for the third consecutive quarter since its launch in Q2 of 2024, the analyst tells investors in a research note. The firm says that while it expects some degree of seasonal headwinds in Q1, it believes the therapy will continue building momentum as Madrigal broadens its prescriber base and deepens its penetration at top targets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal price target raised to $405 from $400 at H.C. Wainwright
- Cautious Outlook on Madrigal Pharmaceuticals Amid Potential Overvaluation and Competitive Pressures
- Madrigal’s Financial Vulnerability: Overreliance on Specialty Pharmacies Threatens Revenue Stability
- Madrigal Pharmaceuticals Reports Strong Rezdiffra Sales
- Buy Rating for Madrigal Pharmaceuticals Driven by Strong Financials and Promising Clinical Trial Results